2026-01-18 - Analysis Report
**Thermo Fisher Scientific Inc. (TMO) Financial Report**

**Company Overview**
Thermo Fisher Scientific Inc. is a global biotechnology product development company.

**Return Comparison**

**Return Rate of Review Stock (TMO)**
41.38%

**Return Rate of S&P 500 (VOO)**
93.36%

**Divergence**
-50.80
**Analysis**: The divergence between the review stock (TMO) and S&P 500 (VOO) is -50.80, indicating that TMO has performed worse than S&P 500.

**Alpha, Beta Analysis**
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018 | 21.0% | 17.1% | 17.0% | 1.1 | 84.1B |
| 2017-2019 | 46.0% | 17.1% | 29.0% | 1.1 | 122.1B |
| 2018-2020 | 22.0% | 17.1% | 1.0% | 0.8 | 175.0B |
| 2019-2021 | 77.0% | 15.0% | 34.0% | 0.8 | 250.7B |
| 2020-2022 | 8.0% | 25.4% | 10.0% | 0.8 | 206.9B |
| 2021-2023 | -30.0% | 28.6% | -31.0% | 0.9 | 199.4B |
| 2022-2024 | -37.0% | 24.4% | -57.0% | 0.9 | 195.4B |
| 2023-2025 | -17.0% | 27.2% | -79.0% | 0.8 | 217.7B |

**Analysis**: The Alpha, Beta analysis shows varying performance for TMO across different years. In some years, TMO performed well (e.g., 2017-2019), while in others it declined significantly (e.g., 2021-2023).

### Recent Stock Price Fluctuations

|  | Value |
| --- | --- |
| Close | $618.72 |
| Last-Market | -0.95% |
| 5-day SMA | $617.55 |
| 20-day SMA | $597.42 |
| 60-day SMA | $581.89 |

**Analysis**: The 20-day and 60-day Simple Moving Averages are below the current close, indicating a possible downtrend.

### RSI, PPO Index, and Delta Pre-Relative Divergence

| Metric | Value |
| --- | --- |
| RSI | 66.79 |
| PPO | 0.30 |
| Hybrid Signal | Buy (Cash 0%) |
| Risk Level | Medium (MRI 0.80) |
| Recent Relative Divergence Change | 2.50 (+): improving |
| 7-day Rank Change | 0 (0): flat |
| 7-day Dynamic Expected Return Change | 0.00 (0): flat |
| Expected Return (%) | -41.00% |

**Analysis**: The Hybrid Signal is "Buy" but the overall performance is weak with a risk level of "Medium".

### Recent News & Significant Events

* Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report? (link)
* Thermo Fisher Scientific (TMO) Valuation After Leadership Shakeup And New AI Lab Partnerships (link)
* Thermo Fisher Scientific Inc. $TMO Stock Position Raised by MGO One Seven LLC (link)
* Here's How Much You'd Have If You Invested $1000 in Thermo Fisher Scientific a Decade Ago (link)
* Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now? (link)
* Lobbying Update: $30,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed (link)

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 651.52 / 750.00 / 575.00

**Analysis**: Analysts are positive about TMO, recommending a "Buy".

### Recent Earnings Analysis

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2025-10-31 | 4.26 | 10.60 B$ |

**Analysis**: TMO has consistently reported high revenues in recent quarters, with EPS also remaining stable.

### Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

**Analysis**: TMO has consistently reported high revenue growth, and its profit margins are relatively stable. The ROE is also moderate, indicating that the company is utilizing its shareholder equity efficiently.

### Comprehensive Analysis

**Summary**: The report shows overall poor performance for TMO compared to S&P 500. The stock price has declined in recent times, and the moving averages indicate a downtrend. The RSI and PPO indices also indicate a weak performance. The recent news and significant events indicate potential issues with leadership and valuation. Analysts are positive about TMO, but the overall performance is weak.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.